| |
Rescue studies are not meant to be taken lightly – logistical hurdles and communication challenges are aplenty. Despite this, Premier Research doesn’t back down. See how our unique advantages helped a sponsor recover a Phase 1 oncology trial: Learn More
Premier Research. Built for Biotech℠ 
|
|
Today’s Big NewsOct 12, 2023 |
| By Nick Paul Taylor BioNTech is flattering Daiichi Sankyo through imitation. Six months after picking up an Enhertu rival, the German biotech has paid $70 million upfront for an antibody-drug conjugate (ADC) directed at a second receptor targeted by Daiichi. |
|
|
|
By Annalee Armstrong A phase 1 study for PepGen’s myotonic dystrophy therapy has been cleared for launch in the U.S. after a five-month FDA clinical hold. |
By Annalee Armstrong There’s a lot of risk inherent in biotech investment, but a new report suggests that an increasingly safe bet is one of the hottest areas of drug development: cell and gene therapy. |
Sponsored by Trinity Life Sciences In a dynamic landscape, three emerging trends have the power to reshape the complexities of pharmaceutical commercialization. |
By James Waldron Almirall will have exclusive global rights to any resulting therapies from the collaboration in return for milestone payments totaling up to $210 million as well as a slice of the royalties. |
Sponsored by IQVIA Greg Lever, Director within the IQVIA Applied Data Science Center, reveals how modeling technology is being used to unlock value and enhance the experience of trial participants. |
By Nick Paul Taylor Ichnos Sciences has finally found a buyer for its OX40 eczema program. Astria Therapeutics has taken the other side of the deal, paying $15 million upfront to secure a spot at the back of a race led by Amgen and Sanofi. |
Sponsored by AnaptysBio AnaptysBio announces top-line data showing rapid clearance of generalized pustular psoriasis (GPP), a rare systemic skin disease |
By Joseph Keenan IQVIA, a leading biopharma data provider, is teaming with the Coalition for Epidemic Preparedness Innovations to advance the “100 Days Mission” focused on streamlining global clinical research for vaccines and other treatments targeting emerging infectious diseases. |
By Joseph Keenan The U.K.’s Medicines and Healthcare products Regulatory Agency established new guidelines that will cut by half the time it takes to approve lower-risk clinical trials. |
By Eric Sagonowsky,Fraiser Kansteiner Just two weeks after Biogen completed its buyout of Reata Pharmaceuticals, the combined company is trimming its staff. Reata staffers who worked in roles that are already covered at Biogen are losing their jobs. |
By Andrea Park A year after unveiling its first blood test aimed at spotting the signs of a range of neurodegenerative diseases, Labcorp is ramping up its offerings in that realm with the launch of a new, Alzheimer’s disease-specific test. |
By Angus Liu Pfizer is expanding the reach of its BRAF-MEK combo as the pharma giant looks to further build up its oncology presence. |
By Noah Tong Despite its costs, interest in covering GLP-1 drugs among employers in 2024 has nearly doubled, according to a new survey. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
|
|---|
|
|
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Edison Ballroom, New York City |
|
|
| |
|
